ArticleFrontiers in veterinary science2025
High seroprevalence of SARS-CoV-2 in cats linked to human infection in a Latin American country with elevated COVID-19 transmission and mortality.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prevalence, Clinical Signs, Diagnosis and Treatment of Post-Pandemic SARS-CoV-2 Infection in Cats in 2023: Co-Infection with FHV, FCV,Veterinary sciences · 2026Article
- Detection of SARS-CoV-2 antibodies in companion animals in Poland during the post-pandemic period (2022-2025).BMC veterinary research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Introduction: SARS-CoV-2 has been shown to infect various animal species, including companion animals such as cats. Although direct transmission from cats to humans has not been confirmed, monitoring the prevalence of infection in these animals remains critical as susceptible hosts to SARS-CoV-2, particularly in regions with high COVID-19 case numbers. This study aimed to evaluate the seroprevalence of SARS-CoV-2 in cats during the first wave of the COVID-19 pandemic in Lima, Peru. Methods: Serum samples from 544 cats, collected between 2020 and 2021, were tested for antibodies using a double antigen sandwich ELISA targeting the receptor-binding protein domain (RBD) and the nucleocapsid (N) proteins. This ELISA has a sensitivity of 80% and a specificity of 100%. Results: A seroprevalence of 43.8% was observed, with higher rates in females (63.9%), kittens (51.3%), and the Domestic Shorthair breed (93.2%). Among owners diagnosed with COVID-19, 95.5% of their cats were seropositive, with no cross-reactivity observed for other common feline diseases. Conclusion: These findings suggest significant SARS-CoV-2 exposure and possible infection in cats during the early pandemic phase in Peru. The high seroprevalence observed highlights the need for ongoing surveillance of companion animals, especially in regions with high human infection rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.